(Q40154586)

18 September 2017

1 reference

title

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases (English)

1 reference

Anesthesiology and pain medicine

18 September 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

4 October 2023

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

4 October 2023

author name string

J. Kovarsky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6348951

4 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6348951

4 October 2023

publication date

1 May 1983

1 reference

full work available at URL

18 September 2017

https://api.elsevier.com/content/article/PII:0049017283900161?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

https://api.elsevier.com/content/article/PII:0049017283900161?httpAccept=text/plain

4 October 2023

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Seminars in Arthritis and Rheumatism

4 October 2023

published in

1 reference

18 September 2017

12

1 reference

18 September 2017

359-372

1 reference

18 September 2017

4

1 reference

Carcinoma of the Urinary Bladder in Patients Receiving Cyclophosphamide

18 September 2017

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1056/NEJM197508072930604

Immunosuppressive Therapy in Rheumatic Disease

3

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Long-term cyclophosphamide therapy in rheumatoid arthritis

4 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive therapy in rheumatoid arthritis

4 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive agents in lupus nephritis: a critical analysis

4 October 2023

12

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

4 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Clinical pharmacology of cyclophosphamide

4 October 2023

15

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy

4 October 2023

16

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution

4 October 2023

17

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice

4 October 2023

19

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Therapeutic efficacy of cyclophosphamide as a function of its metabolism

4 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1a

4 October 2023

22

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

[First experience in treating malignant tumors with a new nitrogen mustard-phosphamidester.]

4 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The clinical pharmacology of antineoplastic agents (second of two parts).

4 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Alkylating properties of phosphoramide mustard

4 October 2023

32

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide

4 October 2023

34

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo

4 October 2023

35

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Urinary metabolites of the antitumor agent cyclophosphamide

4 October 2023

39

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Metabolism of cyclophosphamide by sheep

4 October 2023

40

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Pharmacokinetics of Cyclophosphamide in Renal Failure

4 October 2023

41

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Hemodialysis in cancer chemotherapy

4 October 2023

43

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Timely appraisal: Ectopic (exocellular) nucleic acid as a drug target, especially in rheumatoid arthritis and certain cancers (?)

4 October 2023

46

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The Effect of Cyclophospkamide on the Immune Response

4 October 2023

48

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Clinical infections, antibiotics and immunosuppression: a puzzling relationship

4 October 2023

49

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Selective depletion of lymphoid tissue by cyclophosphamide

4 October 2023

50

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine- 125 I and 51 Cr.

4 October 2023

51

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with wegener's granulomatosis

4 October 2023

54

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Specific Acquired Immune Unresponsiveness to Contact Allergens with Cyclophosphamide in the Mouse

4 October 2023

55

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide

4 October 2023

56

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The effect of cytotoxic drugs on graft-versus-host disease in mice.

4 October 2023

57

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Tolerance to Polyinosinic ⋅ Polycytidylic Acid in NZB/ NZW Mice

4 October 2023

58

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

4 October 2023

59

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Influence of cyclophosphamide on the delayed hypersensitivity of the mouse

4 October 2023

61

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide

4 October 2023

62

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse

4 October 2023

63

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

4 October 2023

64

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors

4 October 2023

65

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

19S and 7S Antibody Production in the Cyclophosphamide- or Methotrexate-treated Rat

4 October 2023

68

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Further studies on B-lymphocyte suppression in delayed hypersensitivity, indicating a possible mechanism for Jones-Mote hypersensitivity

4 October 2023

72

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Enhancing effect of low dose cyclophosphamide treatment on the in vitro antibody response

4 October 2023

73

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases

4 October 2023

74

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Effects of cyclophosphamide on B- and T-lymphocytes in rheumatoid arthritis

4 October 2023

75

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Inductionin vitro of reversible immunosuppression and inhibition of B cell receptor regeneration by defined metabolites of cyclophosphamide

4 October 2023

77

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyt

4 October 2023

78

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration

4 October 2023

81

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Intensive cyclophosphamide (NSC-26271) therapy for solid tumors

4 October 2023

82

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma

4 October 2023

83

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide and urinary bladder toxicity

4 October 2023

85

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN

4 October 2023

86

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide hemorrhagic cystitis

4 October 2023

87

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Bladder Toxicity With Chronic Oral Cyclophosphamide Therapy in Nonmalignant Disease

4 October 2023

88

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

4 October 2023

89

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications

4 October 2023

90

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide necrosis of bladder causing calcification, contracture and reflux; treated by colocystoplasty

4 October 2023

91

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy

4 October 2023

92

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Does cyclophosphamide induce bladder cancer?

4 October 2023

97

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The Incidence Of Bladder Cancer after Cyclophosphamide Therapy

4 October 2023

98

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide and the bladder

4 October 2023

99

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Gonadal dysfunction in patients receiving chemotherapy for cancer

4 October 2023

101

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Sterility and testicular atrophy related to cyclophosphamide therapy

4 October 2023

102

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide and reproductive function.

4 October 2023

103

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Gonadotropin Response to Luteinizing Hormone-Releasing Hormone in Men with Germinal Aplasia

4 October 2023

105

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclical combination chemotherapy and gonadal function. Retrospective study in males

4 October 2023

107

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The effect of alkylating agents on the reproductive and hormonal testicular function in patients with rheumatoid arthritis

4 October 2023

108

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Return of fertility in a patient with cyclophosphamide-induced azoospermia

4 October 2023

110

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents

4 October 2023

111

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Multiple late complications of therapy with cyclophosphamide, including ovarian destruction

4 October 2023

112

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide-Induced Ovarian Failure

4 October 2023

113

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Sterility and cyclophosphamide

4 October 2023

114

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Pregnancy outcome following cancer chemotherapy

4 October 2023

115

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma)

4 October 2023

116

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

CONGENITAL ANOMALIES PROBABLY INDUCED BY CYCLOPHOSPHAMIDE

4 October 2023

117

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Fetal effects during cyclophosphamide and irradiation therapy

4 October 2023

118

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Genetic effects of cyclophosphamide, ifosfamide and trofosfamide

4 October 2023

119

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Experimental studies on the genesis of limb malformations produced in chicken embryos with nitrogen mustard

4 October 2023

120

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW MICE

4 October 2023

123

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Acute leukemia in rheumatoid arthritis treated with cytotoxic agents

4 October 2023

125

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive Drugs and Acute Leukemia

4 October 2023

126

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Acute leukemia complicating metastatic breast cancer

4 October 2023

127

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens

4 October 2023

128

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

AN ASSOCIATION BETWEEN THE RHEUMATIC DISEASES AND THE RETICULOSES

4 October 2023

129

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Alopecia activity of cyclophosphamide metabolites and related compounds in sheep

4 October 2023

130

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide

4 October 2023

135

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Comparison of the cardiovascular actions of NSC-109,724 (ifosfamide) and cyclophosphamide.

4 October 2023

136

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Pathology of high dose intermittent cyclophosphamide therapy

4 October 2023

137

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cytotoxic drug-induced pulmonary disease: update 1980.

4 October 2023

138

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide

4 October 2023

139

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Effect of steroid hormone on activation of Endoxan (cyclophosphamide)

4 October 2023

140

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Plasma levels and urinary excretion of ( 14 C)cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone

4 October 2023

143

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Impairment of drug metabolism in man by allopurinol and nortriptyline

4 October 2023

145

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation.

4 October 2023

149

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus

4 October 2023

150

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Massive hepatic necrosis after cyclophosphamide

4 October 2023

151

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide in solid tumors

4 October 2023

154

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Generalized urticaria to cyclophosphamide: Type I hypersensitivity to an immunosuppressive agent

4 October 2023

156

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Oropharyngeal sensation associated with rapid intravenous administration of cyclophosphamide (NSC-26271)

4 October 2023

157

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Letter: Cyclophosphamide-induced nail pigmentation

4 October 2023

158

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide: Use in Practice

4 October 2023

159

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Editorials: Immunosuppressive therapy in lupus erythematosus

4 October 2023

160

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A New Therapeutic Strategy in Systemic Vasculitis?

4 October 2023

161

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Randomized versus historical controls for clinical trials.

4 October 2023

162

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive therapy of immunoinflammatory diseases

4 October 2023

164

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

4 October 2023

165

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

4 October 2023

166

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment

4 October 2023

167

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Double-blind study of cyclophosphamide in rheumatoid arthritis

4 October 2023

168

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Proceedings: A double-blind comparative trial of cyclophosphamide and gold in rheumatoid arthritis

4 October 2023

169

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Controlled trial of cyclophosphamide in rheumatoid arthritis

4 October 2023

170

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A combined clinical and immunological assessment of four cyclophosphamide regimes in rheumatoid arthritis

4 October 2023

172

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Toxicity of immunosuppressive drugs in man

4 October 2023

173

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes

4 October 2023

175

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide in Treatment of Systemic Lupus Erythematosus: 7 Years' Experience

4 October 2023

178

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide in systemic lupus erythematosus

4 October 2023

179

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide in the treatment of systemic lupus erythematosus

4 October 2023

180

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Corticosteroid Therapy of the Collagen Vascular Disorders

4 October 2023

181

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

4 October 2023

183

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

4 October 2023

184

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide in lupus nephritis: a controlled trial

4 October 2023

185

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

4 October 2023

187

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis

4 October 2023

188

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

4 October 2023

189

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Regimens for treatment of lupus nephritis

4 October 2023

190

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Systemic lupus erythematosus--survival patterns. Experience with 609 patients

4 October 2023

191

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis

4 October 2023

192

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death

4 October 2023

193

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Hematologic aspects of systemic lupus erythematosus. Current concepts

4 October 2023

194

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Pulmonary hypertension in a child with mixed connective tissue disease

4 October 2023

196

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Wegener's granulomatosis: studies in eighteen patients and a review of the literature

4 October 2023

197

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Wegener's granulomatosis. Long-term followup of patients treated with cyclophosphamide

4 October 2023

198

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Treatment of Wegener's granulomatosis of lung

4 October 2023

199

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis and granulomatosis of lung. Recognition and treatment

4 October 2023

200

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Wegener's granulomatosis: successful treatment with high-dose cyclophosphamide

4 October 2023

202

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Lymphomatoid granulomatosis. Report of a case and review of the literature

4 October 2023

203

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years

4 October 2023

204

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis

4 October 2023

206

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide-induced remissions in advanced polyarteritis nodosa

4 October 2023

207

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive and corticosteroid therapy of polyarteritis nodosa

4 October 2023

208

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Onset of polyarteritis nodosa during allergic hyposensitization treatment

4 October 2023

209

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Polyarteritis nodosa, hairy cell leukemia and splenosis

4 October 2023

211

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients

4 October 2023

212

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive therapy in polymyositis

4 October 2023

213

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis

4 October 2023

214

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis

4 October 2023

215

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group

4 October 2023

216

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients

4 October 2023

217

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Biologic and clinical significance of cryoglobulins. A report of 86 cases

4 October 2023

218

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Intestinal vasculitis in essential, mixed cryoglobulinemia.

4 October 2023

219

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients

4 October 2023

220

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement

4 October 2023

221

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide therapy of Behcet's disease

4 October 2023

223

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome

4 October 2023

224

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Plasmapheresis and immunosuppressive drug therapy in scleroderma

4 October 2023

225

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome

4 October 2023

226

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cytotoxic drugs in steroid-resistant renal disease. Alkylating and antimetabolic agents in the treatment of nephrotic syndrome, lupus nephritis, chronic glomerulonephritis, and purpura nephritis in children

4 October 2023

227

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

Cyclophosphamide therapy for severe juvenile rheumatoid arthritis

4 October 2023

228

1 reference

https://api.crossref.org/works/10.1016/0049-0172(83)90016-1

4 October 2023

Identifiers

1 reference

18 September 2017

1 reference